Literature DB >> 26002258

All plasma products are not created equal: Characterizing differences between plasma products.

Philip C Spinella1, Elfaridah Frazier, Heather F Pidcoke, Dennis J Dietzen, Shibani Pati, Oleg Gorkun, James K Aden, Philip J Norris, Andrew P Cap.   

Abstract

BACKGROUND: Plasma can be manufactured by multiple methods. Few studies have compared quality parameters between plasma products that may affect efficacy and safety.
METHODS: Four different plasma products were analyzed to include fresh frozen plasma (FFP), liquid plasma (LP), solvent detergent plasma (SDP), and a spray-dried, solvent detergent-treated plasma (SD-SDP) at multiple time points of storage. Parameters measured included red blood cell, platelet, and white blood cell counts; microparticle phenotypes; thrombin generation; and thrombelastography. These parameters were compared in 10 samples of each product.
RESULTS: SDP and SD-SDP contained the smallest number of residual cells compared with FFP and LP. Platelets were the most common residual cell in all products and were highest in LP. FFP contained the greatest number of residual red blood cells. Total microparticle counts were elevated in LP and FFP compared with SDP and SD-SDP. Cell-derived microparticles in both LP and FFP were mostly platelet in origin. Microparticle counts in SDP and SD-SDP were negligible. Thrombelastography results demonstrated similar thrombin, fibrinogen, and platelet function on Day 28 LP compared with Day 5 thawed FFP. Thrombin generation assays revealed that the total, lag time to, and peak thrombin formation were higher in SDP and SD-SDP compared with FFP and LP. All parameters in FFP and LP products were characterized by a large degree of variability.
CONCLUSION: The differences in cellular, microparticle, and functional hemostatic parameters measured between plasma products have the potential to affect efficacy and safety. Further study is needed to elucidate the potential immune effects of the cellular and microparticle differences noted as well as the clinical implications of altered thrombin generation kinetics in SD products.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26002258     DOI: 10.1097/TA.0000000000000629

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  11 in total

1.  Blood manufacturing methods affect red blood cell product characteristics and immunomodulatory activity.

Authors:  Ruqayyah J Almizraq; Philip J Norris; Heather Inglis; Somaang Menocha; Mathijs R Wirtz; Nicole Juffermans; Suchitra Pandey; Philip C Spinella; Jason P Acker; Jennifer A Muszynski
Journal:  Blood Adv       Date:  2018-09-25

2.  What Laboratory Tests and Physiologic Triggers Should Guide the Decision to Administer a Platelet or Plasma Transfusion in Critically Ill Children and What Product Attributes Are Optimal to Guide Specific Product Selection? From the Transfusion and Anemia EXpertise Initiative-Control/Avoidance of Bleeding.

Authors:  Meghan Delaney; Oliver Karam; Lani Lieberman; Katherine Steffen; Jennifer A Muszynski; Ruchika Goel; Scot T Bateman; Robert I Parker; Marianne E Nellis; Kenneth E Remy
Journal:  Pediatr Crit Care Med       Date:  2022-01-01       Impact factor: 3.971

3.  Characteristics of Extracellular Vesicles in Red Blood Concentrates Change with Storage Time and Blood Manufacturing Method.

Authors:  Ruqayyah J Almizraq; Jelena L Holovati; Jason P Acker
Journal:  Transfus Med Hemother       Date:  2018-03-16       Impact factor: 3.747

4.  Is all plasma created equal? A pilot study of the effect of interdonor variability.

Authors:  Amanda M Chipman; Shibani Pati; Daniel Potter; Feng Wu; Maximillian Lin; Rosemary A Kozar
Journal:  J Trauma Acute Care Surg       Date:  2020-01       Impact factor: 3.697

5.  Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study.

Authors:  Cassandra D Josephson; Stuart Goldstein; David Askenazi; Claudia S Cohn; Philip C Spinella; Ara Metjian; Ross M Fasano; Lejla Music-Aplenc
Journal:  Transfusion       Date:  2021-12-20       Impact factor: 3.337

6.  Washing or filtering of blood products does not improve outcome in a rat model of trauma and multiple transfusion.

Authors:  Mathijs R Wirtz; Jordy Jurgens; Coert J Zuurbier; Joris J T H Roelofs; Philip C Spinella; Jennifer A Muszynski; J Carel Goslings; Nicole P Juffermans
Journal:  Transfusion       Date:  2018-11-21       Impact factor: 3.157

Review 7.  Targeting repair of the vascular endothelium and glycocalyx after traumatic injury with plasma and platelet resuscitation.

Authors:  Mark Barry; Shibani Pati
Journal:  Matrix Biol Plus       Date:  2022-03-17

Review 8.  Transfusion-related immunomodulation: review of the literature and implications for pediatric critical illness.

Authors:  Jennifer A Muszynski; Philip C Spinella; Jill M Cholette; Jason P Acker; Mark W Hall; Nicole P Juffermans; Daniel P Kelly; Neil Blumberg; Kathleen Nicol; Jennifer Liedel; Allan Doctor; Kenneth E Remy; Marisa Tucci; Jacques Lacroix; Philip J Norris
Journal:  Transfusion       Date:  2016-10-02       Impact factor: 3.157

9.  Group A emergency-release plasma in trauma patients requiring massive transfusion.

Authors:  Amory de Roulet; Jeffrey D Kerby; Jordan A Weinberg; Richard H Lewis; Jay P Hudgins; Ira A Shulman; Erin E Fox; John B Holcomb; Karen J Brasel; Eileen M Bulger; Mitchell Jay Cohen; Bryan A Cotton; Timothy C Fabian; Terence O'Keeffe; Sandro Rizoli; Thomas M Scalea; Martin A Schreiber; Kenji Inaba
Journal:  J Trauma Acute Care Surg       Date:  2020-12       Impact factor: 3.697

10.  Treating the endotheliopathy of SARS-CoV-2 infection with plasma: Lessons learned from optimized trauma resuscitation with blood products.

Authors:  Shibani Pati; Erin Fennern; John B Holcomb; Mark Barry; Alpa Trivedi; Andrew P Cap; Matthew J Martin; Charles Wade; Rosemary Kozar; Jessica C Cardenas; Joseph F Rappold; Renee Spiegel; Martin A Schreiber
Journal:  Transfusion       Date:  2021-07       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.